Promimic

18.95

SEK

-7.11 %

Less than 1K followers

PRO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Ownership

Investor consensus

Promimic specializes in biotechnology. The company conducts research and development in surface modifications. Examples of specialist areas include surface modifications for osseointegration for orthopedic and dental implants. The main operations are in Europe and America, where research and development are conducted in-house but also through partners.

Market cap

358.01M SEK

Turnover

47.58K SEK

Revenue

43.98M

EBIT %

-18.92 %

P/E

-

Dividend yield-%

-

Financial calendar

22/8

2025

Interim report Q2'25

19/11

2025

Interim report Q3'25

24/2

2026

Annual report '25

All

Press releases

ShowingAll content types

Regulatory press release5/22/2025, 2:00 PM

Kommuniké från årsstämma 2025 i Promimic AB (publ)

Regulatory press release5/15/2025, 5:30 AM

Promimic AB: Strategiska affärer för tillväxt i Kvartal 1 2025

Press release5/5/2025, 2:00 PM

Promimic AB: Fördjupat samarbete med Curiteva

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release4/23/2025, 7:00 AM

Promimic AB: Strategiskt samarbetsavtal med Lincotek

Regulatory press release4/17/2025, 5:30 AM

Kallelse till årsstämma i Promimic AB (publ)

Regulatory press release4/10/2025, 6:00 AM

Promimic AB: Promimic Årsredovisning 2024

Regulatory press release3/3/2025, 10:15 AM

VD:n säljer del av sitt aktieinnehav i Promimic AB (publ)

Regulatory press release2/25/2025, 6:30 AM

Promimic AB: Promimic Bokslutskommuniké 2024 och Kvartal 4: All-Time-High

Press release2/17/2025, 3:00 PM

Promimic AB: Nya resultat visar att beläggning av implantat med HA[nano] Surface minskar förekomsten av bakterier

Regulatory press release11/21/2024, 6:30 AM

Promimic AB: Tillväxt och tio nya godkännanden under tredje kvartalet

Regulatory press release10/15/2024, 5:30 AM

Valberedning utsedd i Promimic AB (publ)

Regulatory press release10/11/2024, 3:30 PM

Promimic AB: Promimic har löst in optionsprogrammet 2021-TO3

Press release9/5/2024, 6:25 PM

Promimic AB: FSG ökar sitt ägande i Promimic

Regulatory press release8/22/2024, 5:30 AM

Promimic AB: Nytt försäljningsrekord och nytt licensavtal under andra kvartalet

Regulatory press release5/22/2024, 4:00 PM

Kommuniké från årsstämma 2024 i Promimic AB (publ)

Regulatory press release5/22/2024, 5:30 AM

Promimic AB: Rekordmånga FDA-godkännanden för Promimics kunder i kvartal 1, 2024

Regulatory press release4/26/2024, 12:00 PM

Promimic AB: Promimic Årsredovisning 2023

Regulatory press release4/19/2024, 8:27 AM

Kallelse till årsstämma i Promimic AB (publ)

Press release3/8/2024, 9:16 AM

Grundarna säljer del av sitt aktieinnehav i Promimic AB (publ)

Regulatory press release2/28/2024, 6:30 AM

Promimic AB: Promimic växer med 129 procent under 2023

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.